The NCE period for tirzepatide runs through May 13, 2027, which means generic companies may not file an ANDA seeking approval for a generic version of Mounjaro or Zepbound until May 13, 2026, with patent infringement lawsuits expected to occur in the following months
Individual results vary based on numerous factors including genetics, adherence, product quality, and overall health status.
The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-ii and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus
The Cysterhood app is loaded with easy, PCOS-friendly, high-protein recipes to make your meals both nourishing and delicious
Further reading [edit] Minerva Endocrinologica
Arbutin ameliorates glucocorticoid-induced osteoporosis through activating autophagy in osteoblasts